{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone%3A+Treatment+C",
    "query": {
      "intervention": "Abiraterone: Treatment C"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone%3A+Treatment+C&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T00:16:45.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01640093",
      "title": "A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate, 250 mg (uncoated, current commercial tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 500 mg (coated, reformulated tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 250 mg (coated, reformulated tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2012-05",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640093"
    },
    {
      "nct_id": "NCT02649790",
      "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)",
        "Metastatic Colorectal Cancer (mCRC)",
        "Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
        "Higher-Risk Myelodysplastic Syndrome (HR-MDS)",
        "Acute Myeloid Leukemia (AML)",
        "Newly Diagnosed Intermediate/High-Risk MDS"
      ],
      "interventions": [
        {
          "name": "KPT-8602",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2016-01",
      "completion_date": "2024-12-23",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649790"
    },
    {
      "nct_id": "NCT02711137",
      "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB057643",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2016-05-18",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02711137"
    },
    {
      "nct_id": "NCT04726332",
      "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Malignant",
        "Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "XL102",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-02-10",
      "completion_date": "2024-05-02",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04726332"
    },
    {
      "nct_id": "NCT05067140",
      "title": "A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "ARV-766",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid (e.g., prednisone/prednisolone)",
          "type": "DRUG"
        },
        {
          "name": "Androgen Deprivation Therapy (ADT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 164,
      "start_date": "2021-09-02",
      "completion_date": "2027-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 17,
      "location_summary": "Duarte, California • La Jolla, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067140"
    },
    {
      "nct_id": "NCT02230046",
      "title": "Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate (Treatment B)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 102,
      "start_date": "2014-10",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230046"
    },
    {
      "nct_id": "NCT01575587",
      "title": "A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacology"
      ],
      "interventions": [
        {
          "name": "Abiraterone: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone: Treatment D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "25 Years to 35 Years · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2012-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575587"
    },
    {
      "nct_id": "NCT02991911",
      "title": "A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MEDI3726 Post-Chemo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI3726 Pre-Chemo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI3726 & Enzalutamide Combo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2017-01-06",
      "completion_date": "2019-09-30",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Sarasota, Florida • Norfolk, Virginia",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02991911"
    },
    {
      "nct_id": "NCT04577833",
      "title": "A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate (AA)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 136,
      "start_date": "2020-11-13",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 1,
      "location_summary": "West Valley City, Utah",
      "locations": [
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04577833"
    },
    {
      "nct_id": "NCT07570979",
      "title": "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "INR731",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Androgen deprivation therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 208,
      "start_date": "2026-05-25",
      "completion_date": "2030-06-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-30T00:16:45.909Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570979"
    }
  ]
}